ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

ASCO Genitourinary Cancers Symposium

S. Tykodi

Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …

Thomas Hutson

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

ASCO Genitourinary Cancers Symposium

M. Dean

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

ASCO Genitourinary Cancers Symposium

R. McKay

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

ASCO Genitourinary Cancers Symposium

N. Haas

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 B…

ASCO 2022 Conference Coverage

L. Albiges

Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy i…

Moffitt Cancer Center

J. Gao

Dual Immunotherapy in RCC

O'Neal Comprehensive Cancer Center at UAB

A. Basu

ESMO 2022 on the Latest in mRCC

ecancer

J. Puente, B. Escudier, V. Grünwald, S. Oudard

Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…

Mário Fontes-Sousa

Choosing Wisely: 1L Combination Treatment for Advanced RCC

Aly-Khan A. Lalani

ESMO 2022 Updates in Renal Cancer

ecancer

T. Choueiri

How I Manage Immune Adverse Events in Solid Tumors

Balazs Halmos

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Yale Cancer Center

D. Braun

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

PrecisCa

M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel